GeoVax Labs, Inc. – NASDAQ:GOVX

Add to watchlist

$0.735

-1.72

-70.13%

Market closed

Open in about 10 hours

-11.51%

month

-11.51%

quarter

+559.52%

year

Market Cap	20.52M
Enterprise value	N/A

P/E	-0.82
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	51.70
Price/Book	0.15
PEG ratio	-0.03
EPS	-14.45

Revenue	N/A
EBITDA	-28.27M
Income	-27.77M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	-22925.62%
Oper. margin	-22936.36%
Gross margin	0%
EBIT margin	-22936.36%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

GeoVax Labs, Inc. (NASDAQ:GOVX): Profit margin
Jun 2023	0	-5.92M
Sep 2023	0	-8.40M
Dec 2023	103.91K	-7.59M	-7306.57%
Mar 2024	0	-5.85M

GeoVax Labs Financials Estimate

Q Y

GeoVax Labs, Inc. (NASDAQ:GOVX): Analyst Estimates
2025	24.3M	-25.8M	-106.17%
2026	133.49M	-5.19M	-3.89%
2027	26.86M	1.99M	7.44%
2028	63.83M	-2.01M	-3.16%

Analysts Price target
Financials & Ratios estimates

GeoVax Labs, Inc. (NASDAQ:GOVX): Debt to assets
Jun 2023	21249062	4.08M	19.23%
Sep 2023	16201031	7.08M	43.71%
Dec 2023	9283219	3.51M	37.92%
Mar 2024	3358182	3.30M	98.38%

GeoVax Labs, Inc. (NASDAQ:GOVX): Cash Flow
Jun 2023	-6.03M	-23.80K	0
Sep 2023	-5.09M	-6.19K	0
Dec 2023	-10.27M	-18.94K	4.06M
Mar 2024	-5.68M	0	0

GeoVax Labs alternative data

GeoVax Labs, Inc. (NASDAQ:GOVX): Employee count
Aug 2023	14
Sep 2023	14
Oct 2023	14
Nov 2023	14
Dec 2023	14
Jan 2024	14
Feb 2024	14
Mar 2024	17
Apr 2024	17
May 2024	17
Jun 2024	17
Jul 2024	17

GeoVax Labs
Hedge Funds Holdings Q1 2023

8.06% -26.91%

of GOVX is owned by hedge funds

10 -9

hedge funds hold GOVX stock

491.66K -1.64M

shares is hold by hedge funds

GOVX hedge funds holdings changes

GeoVax Labs, Inc. (NASDAQ:GOVX): Insider trades (number of shares)
Period	Buy	Sel
Apr 2023	40000	0
Aug 2023	45087	0
Sep 2023	9653	0
Dec 2023	13888	0
Feb 2024	2000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	7 Feb 2024	REYNOLDS MARK officer: CFO officer: CFO	Common Stock	2,000	$2.77	$5,540
Purchase	22 Dec 2023	MCKEE KELLY T. JR. officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	13,888	$0.36	$5,000
Purchase	25 Sep 2023	MCKEE KELLY T. JR. officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	9,653	$0.52	$5,020
Purchase	25 Aug 2023	DODD DAVID A director, officer..	Common Stock	35,087	$0.57	$20,000
Purchase	18 Aug 2023	REYNOLDS MARK officer: CFO officer: CFO	Common Stock	10,000	$0.52	$5,180
Purchase	24 Apr 2023	DODD DAVID A director, officer..	Common Stock	32,000	$0.64	$20,448
Purchase	20 Apr 2023	REYNOLDS MARK officer: CFO officer: CFO	Common Stock	8,000	$0.63	$5,040
Purchase	21 Sep 2022	CHASE RANDAL D director director	Common Stock	10,000	$1.1	$11,000
Purchase	1 Jul 2022	SHARKEY JOHN W. officer: VP, Business Development officer: VP, Business Development	Common Stock	1,000	$0.82	$820
Purchase	27 Jun 2022	MCKEE KELLY T. JR. officer: Chief Medical Officer officer: Chief Medical Officer	Common Stock	4,464	$1.12	$5,000

GeoVax Labs
Earnings Call Transcripts

Quarter	Transcript
Q1 2024 14 May 2024	Q1 2024 Earnings Call Transcript
Q4 2023 1 Mar 2024	Q4 2023 Earnings Call Transcript
Q3 2023 8 Nov 2023	Q3 2023 Earnings Call Transcript
Q2 2023 9 Aug 2023	Q2 2023 Earnings Call Transcript

GOVX earnings call transcripts

GeoVax Labs
Executives

Insider	Age	Compensation
Mr. David Alan Dodd (1950) Chairman, Pres & Chief Executive Officer	75	$420,980
Mr. Mark W. Reynolds CPA, CPA (1962) Chief Financial Officer & Corporation Sec.	63	$357,390
Dr. Mark J. Newman Ph.D. (1955) Chief Scientific Officer	70	$137,080

GeoVax Labs
Latest News

Monday, 9 December 2024
09:00	GeoVax Receives Notice of Allowance For Cancer Vaccine Patent	globenewswire.com
Friday, 29 November 2024
08:02	3 Penny Stocks Ready to Break Out in 2025	marketbeat.com
Tuesday, 26 November 2024
09:00	GeoVax to Present at the Noble Capital Markets Twentieth Annual Emerging Growth Equity Conference	globenewswire.com
Tuesday, 12 November 2024
23:33	GeoVax Labs, Inc. (GOVX) Q3 2024 Earnings Call Transcript	seekingalpha.com
16:00	GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Tuesday, 5 November 2024
09:00	GeoVax to Report Third Quarter 2024 Financial Results and Provide Corporate Update on November 12, 2024	globenewswire.com
Wednesday, 2 October 2024
09:00	GeoVax to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference	globenewswire.com
Tuesday, 3 September 2024
09:00	GeoVax to Participate in Upcoming Investor Conferences in September	globenewswire.com
Wednesday, 28 August 2024
20:59	GeoVax to Raise Approximately $5.0 Million of Gross Proceeds in Offering Priced At-the-Market	globenewswire.com
Tuesday, 27 August 2024
10:55	Should You Buy GeoVax Labs Inc. (GOVX) After Golden Cross?	zacks.com
Tuesday, 20 August 2024
09:29	GeoVax Labs: Is This Micro-Cap Biotech Stock a Boom or a Bust?	marketbeat.com
08:09	GeoVax's stock slides 20% after company raises $8.5 million in stock sale	marketwatch.com
07:45	GeoVax to Raise Approximately $8.5 Million of Gross Proceeds in Offering Priced Above-the-Market	globenewswire.com
Monday, 19 August 2024
12:11	WHO Declares Monkeypox Public Emergency: 5 Mpox Stocks to Watch	zacks.com
07:30	GeoVax's stock soars 54% to lead rally in companies developing mpox treatments	marketwatch.com
Thursday, 15 August 2024
09:00	GeoVax to Present at the Emerging Growth Conference on August 21, 2024	globenewswire.com
Saturday, 10 August 2024
06:15	GeoVax Labs, Inc. (GOVX) Q2 2024 Earnings Call Transcript	seekingalpha.com
Thursday, 8 August 2024
09:00	GeoVax Appoints Teresa Lambe, Acclaimed Professor of Vaccinology and Immunology at the Oxford Vaccine Group, to Its Scientific Advisory Board	globenewswire.com
Tuesday, 6 August 2024
16:00	GeoVax Reports Second Quarter 2024 Financial Results and Provides Business Update	globenewswire.com
Wednesday, 31 July 2024
10:15	Update: GeoVax Announces Phase 2 Plans for Gedeptin® Cancer Therapy Following Clinical Advisory Committee Review	globenewswire.com
Tuesday, 16 July 2024
12:54	GeoVax (GOVX) Stock Pops Ahead of July 18 Catalyst	investorplace.com
Thursday, 27 June 2024
14:23	Why Is GeoVax (GOVX) Stock Up 110% Today?	investorplace.com
Tuesday, 14 May 2024
20:01	GeoVax Labs, Inc. (GOVX) Q1 2024 Earnings Call Transcript	Seeking Alpha
Thursday, 28 March 2024
09:00	GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress	GlobeNewsWire
Tuesday, 12 March 2024
09:00	GeoVax to Present at the 36th Annual Roth Conference	GlobeNewsWire
Friday, 1 March 2024
02:34	GeoVax Labs, Inc. (GOVX) Q4 2023 Earnings Call Transcript	Seeking Alpha
Thursday, 22 February 2024
09:00	GeoVax to Report 2023 Financial Results and Provide Corporate Update on February 29, 2024	GlobeNewsWire
Monday, 19 February 2024
09:00	GeoVax to Present at the 2024 BIO CEO & Investor Conference	GlobeNewsWire
Wednesday, 27 December 2023
09:00	GeoVax to Present at Biotech Showcase During J.P. Morgan Healthcare Week 2024	GlobeNewsWire
Wednesday, 8 November 2023
21:26	GeoVax Labs, Inc. (GOVX) Q3 2023 Earnings Call Transcript	Seeking Alpha

Frequently Asked Questions (FAQ)

What's the price of GeoVax Labs stock today?

One share of GeoVax Labs stock can currently be purchased for approximately $0.73.
When is GeoVax Labs's next earnings date?

Unfortunately, GeoVax Labs's (GOVX) next earnings date is currently unknown.
Does GeoVax Labs pay dividends?

No, GeoVax Labs does not pay dividends.
How much money does GeoVax Labs make?

GeoVax Labs has a market capitalization of 20.52M.
What is GeoVax Labs's stock symbol?

GeoVax Labs, Inc. is traded on the NASDAQ under the ticker symbol "GOVX".
What is GeoVax Labs's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of GeoVax Labs?

Shares of GeoVax Labs can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Who are GeoVax Labs's key executives?
GeoVax Labs's management team includes the following people:
- Mr. David Alan Dodd Chairman, Pres & Chief Executive Officer(age: 75, pay: $420,980)
- Mr. Mark W. Reynolds CPA, CPA Chief Financial Officer & Corporation Sec.(age: 63, pay: $357,390)
- Dr. Mark J. Newman Ph.D. Chief Scientific Officer(age: 70, pay: $137,080)
How many employees does GeoVax Labs have?

As Jul 2024, GeoVax Labs employs 17 workers.
When GeoVax Labs went public?

GeoVax Labs, Inc. is publicly traded company for more then 4 years since IPO on 25 Sep 2020.
What is GeoVax Labs's official website?

The official website for GeoVax Labs is geovax.com.
Where are GeoVax Labs's headquarters?

GeoVax Labs is headquartered at 1900 Lake Park Drive, Smyrna, GA.
How can i contact GeoVax Labs?

GeoVax Labs's mailing address is 1900 Lake Park Drive, Smyrna, GA and company can be reached via phone at +678 3847220.

GeoVax Labs, Inc.

geovax.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.

+678 3847220

1900 Lake Park Drive
Smyrna, GA 30080

CIK: 0000832489
ISIN: US3736786068
CUSIP: 373678507